Form 4: Bristol Myers Squibb Director Acquires Deferred Share Units

Bristol Myers Squibb Director Phyllis R. Yale acquired 3,996.367 Deferred Share Units, increasing her beneficial ownership.

Summary

• Phyllis R. Yale, a Director of Bristol Myers Squibb Co (BMY), acquired 3,996.367 Deferred Share Units (DSUs).
• The transaction date for this acquisition was February 1, 2026.
• Each DSU is valued at $55.05 and will convert into one share of common stock upon settlement.
• Following this transaction, Phyllis R. Yale beneficially owns a total of 43,326.695 Deferred Share Units.
• These DSUs become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.
• The total beneficial ownership includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, as a director's increased stake, even in deferred units, suggests confidence in the company's long-term value.

Positives

• A director's acquisition of additional Deferred Share Units signals continued confidence in the company's long-term prospects and strategic direction.
• The increase in beneficial ownership aligns the director's interests more closely with those of shareholders.

Future Outlook

Deferred Share Units will be converted into shares of common stock upon the reporting person ceasing to be a director or at a future date previously specified by the reporting person.

Industry Context

StockSavvy.ai notes that insider transactions, such as a director acquiring deferred equity, are often viewed by the market as a positive signal, indicating management's belief in the company's future performance, particularly within the stable pharmaceutical industry.

Stakeholder Impact

• Shareholders may interpret the director's increased beneficial ownership as a positive indicator of management's commitment and belief in the company's future, potentially bolstering investor confidence.

Next Steps

• Settlement of the Deferred Share Units into common stock upon the director's departure or a pre-specified future date.

Key Dates

Recommendation

The director's acquisition of deferred share units, while a positive signal of confidence, is a routine insider transaction and not significant enough on its own to warrant a change from a 'hold' recommendation for a large, established company like Bristol Myers Squibb. It reinforces a stable outlook.

Keywords

Bristol Myers Squibb, BMY, Director, Insider Transaction, Form 4, Deferred Share Units, Equity Acquisition, Corporate Governance